A Phase I Study of CG-7321 Monotherapy or Combination Therapy in Advanced Solid Tumors

This is a Phase I, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of CG-7321 capsules as monotherapy or in combination with fulvestrant in subjects with advanced solid tumors. The study consists of: * Part Ia (Monotherapy): Dose escalation (accelerated titration followed by 3+3 design) from 2mg to 50mg twice daily (BID), plus dose expansion cohorts in advanced solid tumors including HR+/HER2- breast cancer, ovarian cancer, gastric cancer, and other tumor types. * Part Ib (Combination Therapy): Dose escalation of CG-7321 co

Trial Details

NCT ID
NCT07923214
Phase
PHASE1
Sponsor
Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • CG-7321
Locations (sample)
  • Fuzhou, Fujian, China|26.06139,119.30611
  • Dalian, Liaoning, China|38.91222,121.60222
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • 1\. Voluntary signed informed consent and compliance with protocol requirements
  • 2\. Age ≥18 years, any gender
  • 3\. Life expectancy ≥12 weeks
  • 4\. Eastern Cooperative Oncology Group(ECOG) performance status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →